Nicola Rode

The Royal Free Hospital

Papers

1

Total Citations

21

H-Index

1

About

Nicola Rode is a leading urologic oncologist whose research focuses on the evidence-based management of small renal masses (SRMs), with a particular emphasis on nephron-sparing treatments. Dr. Rode’s major contribution is pioneering high-level clinical trial methodology in a field historically lacking robust randomized data. As the lead author of the landmark NEST (Nephron Sparing Treatment) feasibility trial, Dr. Rode demonstrated that a cohort-embedded randomized controlled design can successfully overcome the accrual challenges that have plagued previous SRM studies. This work directly compared percutaneous cryoablation (CRA) to robot-assisted partial nephrectomy (RAPN), providing critical feasibility data that paves the way for larger, definitive trials. The NEST trial, published in 2023 and already cited 21 times, has been recognized as a pivotal step toward establishing comparative effectiveness evidence for these competing minimally invasive approaches. Dr. Rode’s research is instrumental in guiding clinical decision-making for patients with small renal masses, balancing oncologic control with renal function preservation. By addressing a critical evidence gap, Dr. Rode is shaping the future standard of care in urologic oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
21
Total Citations
21
Avg Citations/Paper
🏆 Most Cited Paper
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy
21 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: The Royal Free Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago